唑来膦酸治疗原发性骨质疏松症的效果观察  

Effects of Zoledronic Acid in Patients with Primary Osteoporosis

作　　者：杨敏[1] 刘佳[2] 范茂丹[1] 孙国栋[1] 周磊[1] 

机构地区：[1]南京军区杭州疗养院海勤疗养区,浙江杭州310002 [2]海军总医院感染控制科,北京100037

出　　处：《现代生物医学进展》2013年第3期533-535,共3页Progress in Modern Biomedicine

摘　　要：目的:研究唑来膦酸在治疗原发性骨质疏松症过程中患者骨密度及疼痛的变化。方法:设计为期两年的随机、前瞻性研究,通过Achilles定量超声(QUS)系统测量骨密度(BMD),进行问卷调查、疼痛评估,共入选60例原发性骨质疏松症患者。随机分为唑来膦酸组和对照组,唑来膦酸组使用唑来膦酸及元素钙治疗;对照组使用元素钙治疗。治疗前后分别进行骨密度测定及疼痛评估,进行对比研究。结果:治疗两年后.与治疗前比较,唑来膦酸组BMD上升(P<0.05);对照组BMD无明显变化(P>0.05)。两组临床获益率分别为73.33%和46.67%,无显著差别(P>0.05)。结论:唑来膦酸治疗原发性骨质疏松症有良好作用,能提高骨密度,对骨质疏松的治疗及预防骨折具有重要的意义。Objective： To investigate the effects of zoledronic acid on bone mineral density （BMD） and pain during treatment of patients with primary osteoporosis. Methods： This design was a two-year randomized and prospective study. A total of 60 patients were selected and randomly divided into zoledronic acid （ZA） group and control group. ZA group was given zoledronic acid and calcium; control groupl calcium. Bone mineral density （BMD）, by Achilles quantitative ultrasound （QUS） systems,was measured and pain was evaluated in the two groups before and after treatment. Results： After two years of treatment, BMD of the patients in ZA group increased （P 〈0.05）,compared with before treatment. In control group, BMD had no significant change （P〉0.05） .The rates of clinical benefit of the two groups were 73.33% and 46.67%（P〉0.05 ）. Conclusion： Zoledronic acid for patients with primary osteoporosis has beneficial effects, which can improve BMD and plays an important role in the treatment of patients with primary osteoporosis and in the prevention of fractures.

关 键 词：唑来膦酸 骨质疏松 强度指数 定量超声 

分 类 号：R445.1[医药卫生—影像医学与核医学]